Obstructive Sleep Apnea Management in People With Spinal Cord Injury

Sponsor
University Hospital, Motol (Other)
Overall Status
Recruiting
CT.gov ID
NCT04962165
Collaborator
(none)
60
1
1
27
2.2

Study Details

Study Description

Brief Summary

The prevalence of obstructive sleep apnea (OSA) is a significantly higher in people after spinal cord injury (SCI) than in the general population. As a positive pressure therapy (CPAP) is often poorly tolerated, a mandibular advancement device (MAD) can be used for the treatment of OSA. The purpose of this study is to determine the efficacy of MAD in people with SCI and to verify their adherence to the therapy.

Condition or Disease Intervention/Treatment Phase
  • Device: Mandibular Advancement Device
N/A

Detailed Description

Obstructive sleep apnea (OSA) is a disorder with serious health consequences. Compared to the general population, a significantly higher prevalence of OSA was found in individuals with spinal cord injury (SCI). As treatment, positive pressure therapy in the respiratory tract during sleep (CPAP) is commonly instituted. However, CPAP therapy is often rejected or poorly tolerated by patients. Alternatively, the American Association of Sleep Medicine recommends the use of Mandibular Advancement Devices (MAD). The MAD prevents the upper airway from collapsing by anterior displacement of the mandible.

The aim of the project is to determine the efficacy of MAD therapy in people with SCI and to verify their adherence to the therapy. The research group will consist of 60-80 subjects. The selection of suitable participants will be based on the results of a polygram. The MAD for a group of subjects with an apnea-hypopnea index (AHI) higher than five will be fabricated using their dental impressions. Subsequently, the subjects will be retested while wearing the MAD and outcomes will be compared. The evaluation will include a set of questionnaires. Adherence to therapy will be checked after three and six months.

The investigators anticipate that the results of the study will confirm the effectiveness of MAD devices in the treatment of OSA in the monitored group. Most importantly, the investigators intend to set a standard for a long-term system of diagnosing and addressing OSA in individuals with SCI.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
60 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Intervention Model Description:
Single Group AssignmentSingle Group Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
Obstructive Sleep Apnea Management in People With Spinal Cord Injury, Treatment Options by Mandibular Advancement Device
Actual Study Start Date :
Aug 1, 2021
Anticipated Primary Completion Date :
Jun 1, 2023
Anticipated Study Completion Date :
Nov 1, 2023

Arms and Interventions

Arm Intervention/Treatment
Experimental: Experimental group

The group of SCI people will use a mandibular advancement device for treatment of obstructive sleep apnea.

Device: Mandibular Advancement Device
The device maintain opened upper airway by moving the lower jaw slightly forward while sleeping.

Outcome Measures

Primary Outcome Measures

  1. Apnea-Hypopnea index (AHI) [through study completion, an average of 6 month]

    The obstructive Apnea-Hypopnea Index is defined as the mean number of obstructive apneas and hypopneas per hour of sleep, thus: the occurrence of 5 to 14 events per hour of sleep means presence of mild apnea, 15 to 29 moderate apnea and ≥ 30 severe apnea. The AHI is derived from overnight polygraphy.

Secondary Outcome Measures

  1. Daytime sleepiness [through study completion, an average of 6 month]

    The Epworth sleepiness scale (ESS) will measure the subjective daytime sleepiness, assesses the propensity to sleep under inappropriate circumstances. The ESS questionnaire consists of 8 questions about daytime sleepiness in various situations. The minimum scale values of 0-7 indicate no likeliness of being abnormally sleepy, the maximum scale values of 16-24 indicate excessive sleepiness.

  2. Quality of life measurement [through study completion, an average of 6 month]

    The WHOQOL-BREF will be used to measure the quality of life. This instrument is a self-administered questionnaire comprising 26 questions on the individual's perceptions of their health and well-being over the previous two weeks. Scores range from 0 to 100 with 100 indicating a higher quality of life.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 70 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • AHI > 5 on polygraphy

  • sufficient set of teeth to hold a splint

  • written informed consent

Exclusion Criteria:
  • use of medication that could affect breathing or sleep

  • oxygen-dependent or decompensated lung disease

  • decompensated congestive heart failure

  • evidence of other sleep disorders (narcolepsy, restless legs syndrome, insomnia)

  • abnormalities of the upper airway

  • periodontal problems and untreated caries

  • mental disorders

Contacts and Locations

Locations

Site City State Country Postal Code
1 Paraple Center - rehab center for SCI people Prague Czechia 150 06

Sponsors and Collaborators

  • University Hospital, Motol

Investigators

  • Study Director: Jiri Kriz, MD, PhD, Spinal Cord Unit, University Hospital Motol

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
Assoc. Prof. Jiri Kriz, MD, PhD, Clinical Professor, University Hospital, Motol
ClinicalTrials.gov Identifier:
NCT04962165
Other Study ID Numbers:
  • SCI_APNEA_2021
First Posted:
Jul 14, 2021
Last Update Posted:
Aug 16, 2021
Last Verified:
Aug 1, 2021
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Assoc. Prof. Jiri Kriz, MD, PhD, Clinical Professor, University Hospital, Motol
Additional relevant MeSH terms:

Study Results

No Results Posted as of Aug 16, 2021